DOCSLIB.ORG

Unmasking the Mysteries of MYC Rajeev M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Unmasking the Mysteries of MYC Rajeev M Unmasking the Mysteries of MYC Rajeev M. Nepal and Alberto Martin J Immunol 2019; 202:2517-2518; ; This information is current as doi: 10.4049/jimmunol.1900186 of October 1, 2021. http://www.jimmunol.org/content/202/9/2517 References This article cites 25 articles, 9 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/202/9/2517.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Unmasking the Mysteries of MYC Rajeev M. Nepal* and Alberto Martin† n the early 1980s, when the oncogenic potential of MYC showing that mitogenic stimulation of cells induced the expres- was established, the scientific community was somewhat sion of MYC in a cell cycle–dependent manner (7) and that I perplexed (1). Contrary to other oncogenes known at MYC played a key role in DNA replication (8, 9). the time, such as HRAS, which induced neoplasia only if it Interestingly, constitutive expression of MYC alone was not harbored mutations in the open reading frame, MYC-induced sufficient to transform B cells. B cell lymphomas arose in Em-myc neoplastic transformation was possible from the activation mice in a stochastic manner between 6 and 83 wk of age (4, 6). In of a nonmutated form (1). Chromosomal translocation into addition, the tumors were mainly monoclonal, but from different the IgH locus is one mechanism by which MYC is overex- stages of B cell development (4). Together, these results suggested pressed to cause cancer and is present in virtually all cases of that further somatic mutations were required for tumorigenesis Downloaded from Burkitt lymphoma in humans and plasmacytomas in rodents and triggered the search for genetic events that cooperate with (2). Another important and unexpected discovery in the early MYC-induced tumorigenesis in the Em-myc murine model. 1980s was the detection of transcriptional enhancers, first in One hallmark of most, if not all, types of cancers is ac- thegenomeoftheSV40virusand subsequently in IgH (3). quired resistance to apoptosis (10). In the early 1990s, the Indeed, the landmark paper published by Jerry Adams and thinking behind the oncogenic mechanism of MYC changed colleagues (4) modeled the Burkitt lymphoma chromosomal when its role was extended beyond cellular prolifera- http://www.jimmunol.org/ translocation by creating the Em-myc mice, which involved tionandimplicatedinactivation-inducedapoptosis(11). coupling the MYC gene to the IgH enhancer (this article This finding explained the early nonlymphomatous state is available at https://www.nature.com/articles/318533a0). in Em-myc mice, in which MYC-induced rapid cellular pro- This transgene converted MYC into a potent oncogene liferation was likely offset by MYC-induced apoptosis, in vivo and predisposed the Em-myc mice to B lymphoid thereby protecting Em-myc mice from tumor development lymphoma/leukemia with 100% penetrance (4). Ever since, (4, 12). Subsequent studies showed that deregulated MYC the Em-myc mouse model has proven invaluable in establishing induced apoptosis by activating the tumor suppressor p53 causal links between this genetic anomaly and the imbalance in via ARF, which ultimately triggered a cohort of genes downstream processes involving cellular division, differentiation, involved in apoptosis and cell cycle arrest (13, 14). by guest on October 1, 2021 and apoptosis, which eventually lead to tumorigenesis. Hence, it was hypothesized that secondary mutations Em-myc mice invariably developed tumors, and these tumors might allow B cells to circumvent MYC-induced apoptosis, corresponded to different stages of B cell ontogeny, including likely resulting in clonal tumors. Indeed, the Em-myc pre-B, immature B, mature B, or mixed pre-B/immature B murine model was critical in identifying MYC-induced (4). The endogenous MYC gene in Em-myc tumors is pathways that promote apoptosis (15); more than half transcriptionally silent, just as in Burkitt lymphoma, likely of tumors arising in Em-myc mice had inactivated the due to negative feedback regulation by MYC expressed from ARF–Mdm2–p53 apoptotic axis (15). Consistent with the translocated allele (4), indicative of tight regulation these findings, Em- myc mice heterozygous for p53 or ARF of MYC in untransformed cells. Further characterization showed accelerated lymphomagenesis (16). However, of these mice revealed that most young Em-myc mice almost one fourth of the analyzed tumors did not have any exhibited a variable period of benign overgrowth of pre– conspicuous signs of perturbations in ARF, p53, or Mdm2, B cells, whereas mature B cells developed in reduced implying that multiple pathways were involved (15). number despite increased cell proliferation (5). Thus, In 1983, Land et al. (17) showed that primary rat embryo the MYC-induced proliferative potential and the availability of fibroblasts only became transformed when MYC was intro- a large pool of rapidly dividing cells likely promoted tumorigen- duced along with RAS, thus pioneering the concept of esis (5, 6). This observation was consistent with early studies oncogene cooperation. Based on these results, the Adams Laboratory showed that BCL-2, which, on its own, was weakly transformative, greatly promoted the immortaliza- m *Pfizer Canada, Kirkland, Quebec H9J 2M5, Canada; and †Department of Immunol- tion of B lineage cells from E -myc mice in vitro (18). ogy, University of Toronto, Toronto, Ontario M5S 1A8, Canada Thus, whereas MYC provided cells with proliferative This work was supported by a grant from the Canadian Institutes of Health Research potential, BCL-2 provided cells with a survival capacity, (Grant PJT153307) to A.M. and their synergy promoted lymphocyte tumorigenesis (18). Address correspondence and reprint requests to Dr. Alberto Martin, University of MYC-dependent oncogene cooperation was, for the first time, Toronto, 1 King’s College Circle 7302, Toronto, ON M5S 1A8, Canada. E-mail address: [email protected] shown in vivo in 1990 with the creation of doubly transgenic Em-bcl-2/myc mice, which developed tumors much faster Copyright Ó 2019 by The American Association of Immunologists, Inc. 0022-1767/19/$37.50 and more synchronously than their Em-myc littermate www.jimmunol.org/cgi/doi/10.4049/jimmunol.1900186 2518 PILLARS OF IMMUNOLOGY counterparts, producing tumors with a more primitive 2. Klein, G., and E. Klein. 1985. Myc/Ig juxtaposition by chromosomal transloca- tions: Some new insights, puzzles and paradoxes. Immunol. Today 6: 208–215. lymphoid origin (12). Consistent with these findings, half 3. Schaffner, W. 2015. Enhancers, enhancers from their discovery to today’s universe of high-grade lymphomas arising from single Bcl-2 transgenic of transcription enhancers. Biol. Chem. 396: 311–327. 4. Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, mice harbored somatic translocations that activated MYC (19). S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by Subsequent studies showed that apoptosis is controlled by the immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. interplay between proapoptotic and antiapoptotic proteins. In Nature 318: 533–538. 5. Langdon, W. Y., A. W. Harris, S. Cory, and J. M. Adams. 1986. The c-myc on- 2004, Egle et al. (20) reported that in the absence of Bim, cogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: which is a major physiological antagonist of Bcl2, Em-myc 11–18. 6.Harris,A.W.,C.A.Pinkert,M.Crawford,W.Y.Langdon,R.L.Brinster,and mice showed accelerated MYC-induced lymphomagenesis, J. M. Adams. 1988. The E mu-myc transgenic mouse. A model for high- the kinetics being similar to the gain of Bcl2 (12). Further incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167: 353–371. characterization revealed that the p53 apoptotic pathway was 7. Kelly, K., B. H. Cochran, C. D. Stiles, and P. Leder. 1983. Cell-specific regulation intact in Bim-deficient Em-myc tumors, indicating that loss of of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35: 603–610. apoptosis due to Bim reduction could be an independent 8.Studzinski,G.P.,Z.S.Brelvi,S.C.Feldman,andR.A.Watt.1986.Par- alternative to loss of p53 function during tumorigenesis. ticipation of c-myc protein in DNA synthesis of human cells. Science 234: 467– These studies have collectively helped the clinical develop- 470. 9. Iguchi-Ariga, S. M., T. Itani, Y. Kiji, and H. Ariga. 1987. Possible function of ment of Bcl2 inhibitors as therapeutic agents of different the c-myc product: Promotion of cellular DNA replication. EMBO J. 6: 2365– malignancies (21, 22). 2371. m 10. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57–70. E -myc tumors arise from early stages of B cell 11. Shi, Y., J. M. Glynn, L. J. Guilbert, T. G. Cotter, R. P. Bissonnette, and development, whereas human Burkitt lymphomas and D. R. Green. 1992. Role for c-myc in activation-induced apoptotic cell death in T Downloaded from cell hybridomas.
Load more

Recommended publications
  • Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and P38
    Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes By Andreas Villunger,* Lorraine A. O’Reilly,* Nils Holler,‡ Jerry Adams,* and Andreas Strasser* From *The Walter and Eliza Hall Institute, Melbourne, Victoria 3050, Australia; and the ‡Institute of Biochemistry, University of Lausanne, Epalinges CH-1066, Switzerland Abstract The short life span of granulocytes, which limits many inflammatory responses, is thought to be influenced by the Bcl-2 protein family, death receptors such as CD95 (Fas/APO-1), stress-acti- vated protein kinases such as p38 mitogen-activated protein kinase (MAPK), and proinflamma- tory cytokines like granulocyte colony-stimulating factor (G-CSF). To clarify the roles of these various regulators in granulocyte survival, we have investigated the spontaneous apoptosis of granulocytes in culture and that induced by Fas ligand or chemotherapeutic drugs, using cells from normal, CD95-deficient lpr, or vav-bcl-2 transgenic mice. CD95-induced apoptosis, which required receptor aggregation by recombinant Fas ligand or the membrane-bound ligand, was unaffected by G-CSF treatment or Bcl-2 overexpression. Conversely, spontaneous and drug-induced apoptosis occurred normally in lpr granulocytes but were suppressed by G-CSF treatment or Bcl-2 overexpression. Although activation of p38 MAPK has been implicated in granulocyte death, their apoptosis actually was markedly accelerated by specific inhibitors of this kinase. These results suggest that G-CSF promotes granulocyte survival largely through the Bcl-2–controlled pathway, whereas CD95 regulates a distinct pathway to apoptosis that is not required for either their spontaneous or drug-induced death.
    [Show full text]
  • To Professor Suzanne Cory AC
    Citation for the Award of the Doctor of Laws (Honoris Causa) to Professor Suzanne Cory AC When Suzanne Cory graduated from the Science Faculty at the University of Melbourne molecular biology was in its infancy. In her enthusiasm for this new science she pursued a PhD in Cambridge at the Medical Research Council’s famed Laboratory of Molecular Biology. Immersed in a culture of discovery, her pioneering PhD studies determined the sequence of a transfer RNA, utilising new technology developed by Fred Sanger, one of the three Nobel Laureates in the institute. After three years’ post‐doctoral work at the University of Geneva, Suzanne Cory returned to Australia with her husband, Jerry Adams, to the Walter and Eliza Hall Institute of Medical Research where they helped to introduce gene‐cloning technology to Australia. Since then, her long association with the Institute, including thirteen years as Director, and with the University of Melbourne, has been instrumental in building the international reputation of both institutions and the strength of the Parkville biomedical research network. Suzanne Cory has made major contributions to advancing the science of immunology, cancer and genetics, in a lifelong dynamic research partnership with Adams. Her work is published widely and cited frequently. The positions held by the many PhD candidates and Post‐Doctoral Fellows she has supervised demonstrate her intergenerational influence in developing scientific leaders for the future. The list of accolades and awards Suzanne Cory has received in recognition of her contributions to science is long and distinguished. She was elected a Fellow of the Australian Academy of Science in 1986 and since has been elected to numerous sister organisations across the globe.
    [Show full text]
  • Huzzah to the Double Helix! It's International DNA Day | Lifehacker
    Huzzah To The Double Helix! It’s International DNA Day | L... http://www.lifehacker.com.au/2013/04/huzzah-to-the-double-h... Business Insider Gizmodo Kotaku Lifehacker PopSugar BellaSugar FabSugar ShopStyle Log In Register Life Work IT Pro RECENTLY ON KOTAKU RECENTLY ON KOTAKU Robin Has A Point In These Hilarious Conference Or Not, We’ll Cherish Superhero Texts These E3 Nintendo Memes Forever HOME Huzzah To The Double Helix! It’s International DNA Day CHRIS JAGER YESTERDAY 9:30 AM Share 5858 Discuss 22 Today is International DNA Day, which this year commemorates 60 years since the scientific paper A Structure for Deoxyribose Nucleic Acid was first published. Here’s what some of Australia’s leading scientists SUBSCRIBE have to say about the importance of the discovery… CONTACT DNA picture from Shutterstock Sixty years ago to the day, James Watson and Francis Crick published a revolutionary paper on the Like Lifehacker Australia 5,616 Followers structure of Deoxyribonucleic acid; the molecular key to all living things otherwise known as DNA. A Follow Lifehacker Australia 11,734 Followers century after Gregor Mendel first began messing about with peas, the final piece of the genetic puzzle had been slotted into place. Subscribe to all stories 15,269 Followers To mark this historic occasion, several Australian scientists have released statements in which they Australian stories 1,859 Followers basically wax lyrical about the wonders of DNA — what better way to start your morning? (And if you’re wondering what the Lifehacker angle is, the answer is quite simple: when someone smarter than you has something to say, it’s usually worth listening!) REGULARS LIFE Professor Suzanne Cory, President of the Australian Academy of Science: Sell Your Stuff And Get Some Extra Cash This Weekend The discovery of the structure of DNA by James Watson and Francis Crick was an epic moment in the history of science.
    [Show full text]
  • A Null C-Myc Mutation Causes Lethality Before 10.5 Days of Gestation in Homozygotes and Reduced Fertility in Heterozygous Female Mice
    Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice Ann C. Davis, 1 Marie Wims, 1 Gerald D. Spotts, 2 Stephen R. Hann, 2 and Allan Bradley 1 tlnstitute for Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030 USA; ~Department of Cell Biology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-2175 USA To directly assess c-myc function in cellular proliferation, differentiation, and embryogenesis, we have used homologous recombination in embryonic stem cells to generate both heterozygous and homozygous c-myc mutant ES cell lines. The mutation is a null allele at the protein level. Mouse chimeras from seven heterozygous cell lines transmitted the mutant allele to their offspring. The analysis of embryos from two clones has shown that the mutation is lethal in homozygotes between 9.5 and 10.5 days of gestation. The embryos are generally smaller and retarded in development compared with their littermates. Pathologic abnormalities include the heart, pericardium, neural tube, and delay or failure in turning of the embryo. Heterozygous females have reduced fertility owing to embryonic resorption before 9.5 days of gestation in 14% of implanted embryos, c-Myc protein is necessary for embryonic survival beyond 10.5 days of gestation; however, it appears to be dispensable for cell division both in ES cell lines and in the the embryo before that time. [Key Words: c-myc; gene targeting; null mutation~ embryonic lethal] Received November 25, 1992; revised version accepted January 25, 1993.
    [Show full text]
  • 2010-2011 Annual Report
    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
    [Show full text]
  • Expression of the Other in T Cells Bim and Bcl-2 Mutually Affect
    Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells Trine N. Jorgensen, Amy McKee, Michael Wang, Ella Kushnir, Janice White, Yosef Refaeli, John W. Kappler and This information is current as Philippa Marrack of September 25, 2021. J Immunol 2007; 179:3417-3424; ; doi: 10.4049/jimmunol.179.6.3417 http://www.jimmunol.org/content/179/6/3417 Downloaded from References This article cites 54 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/179/6/3417.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells1 Trine N. Jorgensen,2* Amy McKee,2*ʈ Michael Wang,2† Ella Kushnir,*ʈ Janice White,*ʈ Yosef Refaeli,** John W.
    [Show full text]
  • Suzanne Cory’S Passion in Every Sense
    NEWS Biomedical research has been Suzanne Cory’s passion in every sense. She has worked to decode the genetic mysteries of the immune system and cancer, has rallied her country to invest in its scientific future, and is married to a fellow scientist from her post-doctoral years. Nature Medicine talked to the Director of the Walter and Eliza Hall Institute in Melbourne to find out why her love affair with science hasn’t waned in intensity over four decades. Suzanne Cory Reinvigorated from trekking in one of New stamp on Cory’s life: “It was an environ- vival in tumorigenesis. Together with Zealand’s most challenging mountain ment steeped in scientific passion and rigor Adams and a PhD student, David Vaux, ranges during a rare break from work, Cory —four Nobel laureates and ambitious post- Cory discovered that BCL-2, the oncogene was brimming with enthusiasm. docs from all around the world, hungry for activated by chromosome translocation in Uppermost is excitement about her in- success. It was there that I realized that human follicular lymphoma, had a very volvement in a consortium bidding for the there are no half measures in science — the different mode of action than all previ- Federal Government’s Biotechnology commitment has to be all or nothing.” ously characterized oncogenes. Rather Center of Excellence—the winner will be And it was there that she met fellow scien- than stimulating cell proliferation, BCL-2 announced later this year. Cory and her tist Jerry Adams. They married and em- promotes cell survival. “Nobody then colleagues have the bold vision of estab- barked on a research career together, dreamed that simply stopping a cell from lishing a Therapeutics Development which began with post-docs in Geneva.
    [Show full text]
  • Perforin-Mediated Suppression of B-Cell Lymphoma
    Perforin-mediated suppression of B-cell lymphoma Paul Bolithoa,b, Shayna E. A. Streeta, Jennifer A. Westwooda, Winfried Edelmannc, Duncan MacGregord,e, Paul Waringf, William K. Murraye,g, Dale I. Godfreyb, Joseph A. Trapania,e, Ricky W. Johnstonea,e, and Mark J. Smytha,e,1 aCancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia; bDepartment of Microbiology and Immunology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia; cDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461; dDepartment of Anatomical Pathology, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia; eDepartment of Pathology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia; fPathology and Diagnostics, Genentech Incorporated, South San Francisco, CA 94080; and gDepartment of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved December 19, 2008 (received for review September 10, 2008) In the present study, we have examined the effect of perforin (pfp) It remained unclear from these prior studies whether a loss of deficiency in 4 models of mouse B-cell lymphomagenesis. We have pfp was a direct cause of lymphoma or led indirectly to its examined pfp loss on the background of either Mlh1 tumor development as a result of loss of immune surveillance normally suppressor allele loss or oncogene expression [Ig heavy chain mediated by extrinsic cytolytic effector function. The avid ability (E␮)-v-Abl, E␮-myc, and vav-bcl2]. Pfp was shown to act as a of WT mice to reject B-cell lymphomas derived from pfp- suppressor of B-cell malignancies characteristically driven by v-Abl deficient mice in a pfp-dependent manner when transplanted or bcl-2, whereas Mlh loss cooperated in accelerating spontaneous supported the latter hypothesis.
    [Show full text]
  • Insights from Bel-2 and Mye: Malignancy Involves Abrogation of Apoptosis As Well As Sustained Proliferation 1 Suzanne Cory, 2'3 David L
    [CANCER RESEARCH(SUPPL.) 59, 1685s-1692s, April 1, 1999] Insights from Bel-2 and Mye: Malignancy Involves Abrogation of Apoptosis as well as Sustained Proliferation 1 Suzanne Cory, 2'3 David L. Vaux, Andreas Strasser, Alan W. Harris, and Jerry M. Adams The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria 3050, Australia It is indeed an enormous honor and pleasure to introduce Drs. Suzanne Cory and Stanley Korsmeyer, this year's winners of the Mott Prize. I think no one would question the view that their seminal experiments radically changed the way we think about the process of cancer. If we look back about 10 or 15 years, programmed celt death was a very interesting phenomenon, but we had no idea what this meant in terms of cancer, although suggestions were made. It was certainly interesting in terms of development, but we had no idea about the mechanisms involved. Of course, all this has changed enormously over the last decade, and in terms of cancer particularly, through the seminal contributions of Suzanne Cory and Stan Korsmeyer and their colleagues. Now we know that not only do cancer cells have to escape proliferation controls, they also have to abolish cell death pathways. Not only is this incredibly important for our understanding of the mechanisms underlying cancer, but the way we think about therapy has been radically altered. And as was said already, it is very exciting and a great coincidence, perhaps, that the Sloan Prize this year is awarded to Bob Horvitz who has used very elegant genetics to dissect cell death pathways in C.
    [Show full text]
  • Course Catalog 2019-2020
    Blackburn College COLLEGE Course Catalog 2019-2020 700 College Ave Carlinville, IL 62626 www.blackburn.edu Admissions: 1-800-233-3550 2019-2020 Course Catalog Statement of Mission Blackburn College links a rigorous and affordable liberal arts education with a unique student-managed Work Program preparing graduates for careers, community engagement, and lifelong learning. COLLEGE The Blackburn Course Catalog is printed on paper containing post-consumer content. Cover design by a student worker as part of the Blackburn College Work Program. 2019-2020 Catalog Blackburn College is a private, four-year liberal arts college located in Carlinville, Illinois. A town of nearly 6,000 people, Carlinville is the county seat of Macoupin County. The beautiful 80 acre campus is 40 miles southwest of Springfield and 60 miles northeast of St. Louis, Missouri. Amtrak stops twice daily, linking the town with other Midwestern cities. Visitors are welcome at Blackburn and offices are open Monday through Friday from 8:00 a.m. to 5:00 p.m. Tour appointments can be made by calling (800) 233-3550, ext. 5517 during business hours; or by writing the Office of Admissions, Blackburn College, Carlinville, Illinois 62626; or by e-mail to [email protected]. Visit our web site at: www.blackburn.edu. 1 EDUCATIONAL OBJECTIVES The Faculty of Blackburn College expects each student to make progress toward achieving each of the following specific objectives of our concept of an effective modern liberal education: (Adopted by the faculty on January 20, 2005). 1. A Blackburn graduate should be able to think and communicate clearly and effectively.
    [Show full text]
  • 2017-2018 Catalog
    2017-2018 Catalog Blackburn College is a private, four-year liberal arts college located in Carlinville, Illinois. A town of nearly 6,000 people, Carlinville is the county seat of Macoupin County. The beautiful 80 acre campus is 40 miles southwest of Springfield and 60 miles northeast of St. Louis, Missouri. Amtrak stops twice daily, linking the town with other Midwestern cities. Visitors are welcome at Blackburn and offices are open Monday through Friday from 8:00 a.m. to 5:00 p.m. Tour appointments can be made by calling (800) 233-3550, ext. 5517 during business hours; or by writing the Office of Admissions, Blackburn College, Carlinville, Illinois 62626; or by e-mail to [email protected]. Visit our web site at: www.blackburn.edu. 1 EDUCATIONAL OBJECTIVES The Faculty of Blackburn College expects each student to make progress toward achieving each of the following specific objectives of our concept of an effective modern liberal education: (Adopted by the faculty on January 20, 2005). 1. A Blackburn graduate should be able to think and communicate clearly and effectively. 2. A Blackburn graduate should be able to demonstrate depth in a field of knowledge. 3. A Blackburn graduate should be able to think critically about the ways in which humanity gains and applies knowledge. Specifically, the graduate should have an informed understanding of a. the aesthetic and intellectual experience of literature and the arts; b. history and the concepts and analytic techniques of social science as modes of understanding current issues, problems, and the nature of human experience; and c.
    [Show full text]
  • Data Analytics for Genomics and Beyond
    4th Annual Meeting of the Arkansas Bioinformatics Consortium AR-BIC 2018 We are an Arkansas Collaborative Community in Bioinformatics Research Data Analytics for Genomics and Beyond Embassy Suites Hotel Little Rock, AR April 23-24th, 2018 Organized by: AR-BIC 2018 4th Annual Meeting Conference Sponsors: AR-BIC 2018 4th Annual Meeting Table of Contents 1. About AR-BIC 1 2. AR-BIC Governance 2 3. Venue and contact details 3 4. Detailed agenda 4 5. List of poster presenters 6 6. Biographies a. Governing Board biographies 8 b. Remarks, Chairs, and Organizers biographies 22 c. Speakers biographies and abstracts 29 7. Poster abstracts 44 Page 1 of 71 AR-BIC 2018 4th Annual Meeting About the Arkansas Bioinformatics Consortium (AR-BIC) Mission: The Arkansas Bioinformatics Consortium (AR-BIC) is a virtual Arkansas-centric bioinformatics community aimed at developing, leveraging and enhancing state-wide collaboration, thus forming a stable environment available to support the Arkansas-wide research, education, training and entrepreneurial/industrial activities in life sciences-related computing. AR-BIC activities are within the general area of life sciences computing in Arkansas. The goals of AR-BIC are to (1) strengthen Arkansas' ability to compete at national and international levels for research funding, (2) enable and facilitate collaboration in research where synergy is identified, (3) enhance education, training and university curricula, and (4) expand Arkansas economic growth and job opportunities. AR-BIC is founded on the belief that we can be more than the sum of our parts, and that in our unity, we can draw strength from our diversity.
    [Show full text]